These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 38217824)

  • 1. Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.
    Sabato V; Beyens M; Toscano A; Van Gasse A; Ebo DG
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):63-71. PubMed ID: 38217824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
    Akin C; Arock M; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
    Valent P; Akin C; Hartmann K; Reiter A; Gotlib J; Sotlar K; Sperr WR; Degenfeld-Schonburg L; Smiljkovic D; Triggiani M; Horny HP; Arock M; Galli SJ; Metcalfe DD
    J Allergy Clin Immunol; 2022 Jun; 149(6):1866-1874. PubMed ID: 35421448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
    Muñoz-González JI; García-Montero AC; Orfao A; Álvarez-Twose I
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):427-434. PubMed ID: 34298172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment options for mast cell activation disease.
    Molderings GJ; Haenisch B; Brettner S; Homann J; Menzen M; Dumoulin FL; Panse J; Butterfield J; Afrin LB
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):671-94. PubMed ID: 27132234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
    Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avapritinib for Systemic Mastocytosis.
    Bose P; Verstovsek S
    Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
    Siebenhaar F; Altrichter S; Bonnekoh H; Hawro T; Hawro M; Michaelis EG; Kantor AM; Chang AT; Youngblood BA; Singh B; Rasmussen HS; Maurer M
    Br J Dermatol; 2023 Oct; 189(5):511-519. PubMed ID: 37290787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of mast cell activation syndrome with sunitinib.
    Afrin LB; Cichocki FM; Patel K; Molderings GJ
    Eur J Haematol; 2015 Dec; 95(6):595-7. PubMed ID: 26072665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
    Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
    Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
    Krauth MT; Mirkina I; Herrmann H; Baumgartner C; Kneidinger M; Valent P
    Clin Exp Allergy; 2009 Nov; 39(11):1711-20. PubMed ID: 19860818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.
    Navarro-Navarro P; Álvarez-Twose I; Pérez-Pons A; Henriques A; Mayado A; García-Montero AC; Sánchez-Muñoz L; González-López O; Matito A; Caldas C; Jara-Acevedo M; Orfao A
    Allergy; 2023 May; 78(5):1347-1359. PubMed ID: 36385619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes.
    Picard M; Giavina-Bianchi P; Mezzano V; Castells M
    Clin Ther; 2013 May; 35(5):548-62. PubMed ID: 23642289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hymenoptera Allergy and Mast Cell Activation Syndromes.
    Bonadonna P; Bonifacio M; Lombardo C; Zanotti R
    Curr Allergy Asthma Rep; 2016 Jan; 16(1):5. PubMed ID: 26714690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review.
    Sabato V; Michel M; Blank U; Ebo DG; Vitte J
    Curr Opin Allergy Clin Immunol; 2021 Oct; 21(5):426-434. PubMed ID: 34292177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the Right Criteria for MCAS.
    Gulen T
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality.
    Rama TA; Torrado I; Henriques AF; Sánchez-Muñoz L; Jara-Acevedo M; Navarro-Navarro P; Caldas C; Mayado A; Muñoz-González J; García-Montero A; Mollejo M; Redondo E; Garbán A; Moreira A; Órfão A; Álvarez-Twose I
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):908-919.e4. PubMed ID: 36535520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.